• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Beneluxa: What are the Prospects for Collective Bargaining on Pharmaceutical Prices Given Diverse Health Technology Assessment Processes?

作者信息

O'Mahony James F

机构信息

Centre for Health Policy and Management, Trinity College Dublin, Dublin, Ireland.

出版信息

Pharmacoeconomics. 2019 May;37(5):627-630. doi: 10.1007/s40273-019-00781-w.

DOI:10.1007/s40273-019-00781-w
PMID:30847759
Abstract
摘要

相似文献

1
Beneluxa: What are the Prospects for Collective Bargaining on Pharmaceutical Prices Given Diverse Health Technology Assessment Processes?比荷卢三国经济联盟：鉴于卫生技术评估流程各异，药品价格集体谈判的前景如何？
Pharmacoeconomics. 2019 May;37(5):627-630. doi: 10.1007/s40273-019-00781-w.
2
How insurers' bargaining power affects drug prices in Medicare Part D.保险公司的议价能力如何影响医疗保险D部分的药品价格。
Natl Bur Econ Res Bull Aging Health. 2009(4):1-2.
3
Collective bargaining among nurses: current issues and future prospects.护士群体的集体谈判：当前问题与未来前景。
Health Care Manage Rev. 1984 Spring;9(2):61-7. doi: 10.1097/00004010-198400920-00008.
4
HTA for pharmaceuticals in Europe: will the mountain deliver a mouse?欧洲药品的卫生技术评估：会雷声大雨点小吗？
Eur J Health Econ. 2020 Feb;21(1):1-5. doi: 10.1007/s10198-019-01103-9.
5
Economic evaluation approaches for new technology.新技术的经济评估方法。
IEEE Eng Med Biol Mag. 2003 May-Jun;22(3):16-7. doi: 10.1109/memb.2003.1213621.
6
[High prices and low clinical benefit: anomalies of the drug market].[高价与低临床效益：药品市场的反常现象]
Epidemiol Prev. 2018 Jan-Feb;42(1):92-93. doi: 10.19191/EP18.1.P092.025.
7
Health care collective bargaining: future dynamics and their impact.医疗保健集体谈判：未来动态及其影响
J Health Hum Resour Adm. 1987 Summer;10(1):33-52.
8
Assessing new health technologies: lessons to be learned from drugs.评估新型卫生技术：从药物中汲取的经验教训。
Med J Aust. 1999 Nov 15;171(10):554-6. doi: 10.5694/j.1326-5377.1999.tb123795.x.
9
Collective bargaining by nurses in Canadian health care: assessing recent trends and emerging claims.加拿大医疗保健领域护士的集体谈判：评估近期趋势和新出现的诉求。
Health Law J. 2003;11:177-98.
10
U.S. physicians seek collective bargaining power.美国医生寻求集体谈判权。
Minn Med. 1998 Mar;81(3):10-8.

引用本文的文献

1
Opportunities and Challenges in Cross-Country Collaboration: Insights from the Beneluxa Initiative.跨国合作中的机遇与挑战：比荷卢经济联盟倡议的见解
J Mark Access Health Policy. 2024 Jul 9;12(3):144-157. doi: 10.3390/jmahp12030012. eCollection 2024 Sep.
2
Impact of Systemic Delays for Patient Access to Oncology Drugs on Clinical, Economic, and Quality of Life Outcomes in Canada: A Call to Action.加拿大肿瘤药物患者获得途径的系统延迟对临床、经济和生活质量结果的影响：行动呼吁。
Curr Oncol. 2024 Mar 11;31(3):1460-1469. doi: 10.3390/curroncol31030110.
3
Four Aspects Affecting Health Economic Decision Models and Their Validation.

本文引用的文献

1
HIQA's Perspective on the Challenges Posed by Evaluations of Screening Programs: A Reply.卫生信息质量管理局对筛查项目评估所带来挑战的看法：一则回应
Value Health. 2019 Jan;22(1):136-138. doi: 10.1016/j.jval.2018.06.021. Epub 2018 Aug 23.
2
Surveying the Cost-Effectiveness of the 20 Procedures with the Largest Public Health Services Waiting Lists in Ireland: Implications for Ireland's Cost-Effectiveness Threshold.调查爱尔兰公共卫生服务等候名单中 20 项程序的成本效益：对爱尔兰成本效益阈值的影响。
Value Health. 2018 Aug;21(8):897-904. doi: 10.1016/j.jval.2018.02.013. Epub 2018 Jun 12.
3
Discounting in Economic Evaluations.
影响健康经济决策模型及其验证的四个方面。
Pharmacoeconomics. 2022 Mar;40(3):241-248. doi: 10.1007/s40273-021-01110-w. Epub 2021 Dec 16.
4
A Comparative Analysis of Pricing and Reimbursement of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Europe.欧洲囊性纤维化跨膜传导调节因子调节剂的定价与报销比较分析
Front Pharmacol. 2021 Nov 8;12:746710. doi: 10.3389/fphar.2021.746710. eCollection 2021.
5
Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications.在欧洲，包括生物类似药在内的长效胰岛素类似物的使用趋势：发现与启示。
Biomed Res Int. 2021 Oct 11;2021:9996193. doi: 10.1155/2021/9996193. eCollection 2021.
6
The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future.当前非洲、亚洲、欧洲和南美洲国家（地区）长效胰岛素类似物（包括生物类似物）的现状；未来的发现和启示。
Front Public Health. 2021 Jun 24;9:671961. doi: 10.3389/fpubh.2021.671961. eCollection 2021.
7
Integrative Review of Managed Entry Agreements: Chances and Limitations.综合管理准入协议审查：机遇与限制。
Pharmacoeconomics. 2020 Nov;38(11):1165-1185. doi: 10.1007/s40273-020-00943-1.
8
Transferability of Economic Evaluations of Treatments for Advanced Melanoma.晚期黑色素瘤治疗的经济评估的可转移性。
Pharmacoeconomics. 2020 Feb;38(2):217-231. doi: 10.1007/s40273-019-00860-y.
经济性评价中的折扣
Pharmacoeconomics. 2018 Jul;36(7):745-758. doi: 10.1007/s40273-018-0672-z.
4
Estimating the Reference Incremental Cost-Effectiveness Ratio for the Australian Health System.估算澳大利亚卫生系统的参考增量成本-效果比。
Pharmacoeconomics. 2018 Feb;36(2):239-252. doi: 10.1007/s40273-017-0585-2.
5
From Good to Better: New Dutch Guidelines for Economic Evaluations in Healthcare.从良好到更佳：荷兰医疗保健经济评估新指南
Pharmacoeconomics. 2016 Nov;34(11):1071-1074. doi: 10.1007/s40273-016-0431-y.
6
HIQA's CEA of Breast Screening: Pragmatic Policy Recommendations are Welcome, but ACERs Reported as ICERs are Not.爱尔兰医疗质量与安全管理局（HIQA）对乳腺筛查的成本效益分析：欢迎提出务实的政策建议，但将增量成本效果比（ACER）报告为增量成本效益比（ICER）则不可取。
Value Health. 2015 Dec;18(8):941-5. doi: 10.1016/j.jval.2015.08.009. Epub 2015 Oct 21.
7
The Irish Cost-Effectiveness Threshold: Does it Support Rational Rationing or Might it Lead to Unintended Harm to Ireland's Health System?爱尔兰的成本效益阈值：它是支持合理配给，还是可能对爱尔兰的医疗系统造成意想不到的损害？
Pharmacoeconomics. 2016 Jan;34(1):5-11. doi: 10.1007/s40273-015-0336-1.
8
Cost-effectiveness of population-based screening for colorectal cancer.基于人群的结直肠癌筛查的成本效益
Br J Cancer. 2013 Mar 19;108(5):1209-10. doi: 10.1038/bjc.2012.490. Epub 2013 Feb 7.